← Back to Search

Orthopedic Implant

Dual Mobility Implants for Hip Dislocation

Phase 4
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary THA for a diagnosis of osteoarthritis or inflammatory arthritis in the setting of a history of prior lumbar or lumbosacral fusion performed at least 6 months prior to their THA
Patients considered high-risk for potential prosthetic dislocation based on the presence of one or more of the following: neuromuscular disorder (e.g. cerebral palsy, Parkinson's disease, history of a stroke), dementia or cognitive impairment, substance or alcohol abuse (>10 drinks per week), acute displaced femoral neck fracture, age > 75 years, inflammatory arthritis, and increased preoperative range of motion (calculated as described by Krenzel et al.: combined flexion, adduction, internal rotation > 115 degrees)
Screening 3 weeks
Treatment Varies
Follow Up 10 years following their index surgical procedure.
Awards & highlights

Study Summary

This trial will compare two types of hip replacements to see which is better for patients at high risk for dislocation.

Who is the study for?
This trial is for adults over 75, or those with a history of lumbar fusion surgery, neuromuscular disorders, cognitive impairments, substance abuse, hip fractures, or inflammatory arthritis. It's not for people under 18 or those who've had previous hip surgeries other than lumbar fusion at least 6 months ago.Check my eligibility
What is being tested?
The study compares two types of hip implants in high-risk patients needing total hip replacement: a traditional single-bearing implant and an advanced dual mobility implant. The goal is to see which one better prevents the dislocation of the artificial joint.See study design
What are the potential side effects?
While specific side effects are not listed here, typical risks from hip implant surgery may include infection, pain at the site of the implant, inflammation around the joint area, dislocation of the new joint and possible need for additional surgeries.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I had hip replacement for arthritis after having spine fusion surgery over 6 months ago.
I am at high risk for hip dislocation due to one or more specific health issues.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years following their index surgical procedure.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years following their index surgical procedure. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Secondary outcome measures
Radiographic signs of loosening and proper component placement.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Dual mobilityExperimental Treatment1 Intervention
Patients in this group will receive a dual mobility hip implant
Group II: Single bearing, traditional hip implantActive Control1 Intervention
Patients in this group will receive a traditional, single-bearing hip implant.

Find a Location

Who is running the clinical trial?

Keck School of Medicine of USCUNKNOWN
5 Previous Clinical Trials
298 Total Patients Enrolled
Rothman Institute OrthopaedicsOTHER
121 Previous Clinical Trials
21,166 Total Patients Enrolled
1 Trials studying Hip Dislocation
322 Patients Enrolled for Hip Dislocation
Rush University Medical CenterLead Sponsor
422 Previous Clinical Trials
163,119 Total Patients Enrolled
1 Trials studying Hip Dislocation
322 Patients Enrolled for Hip Dislocation

Media Library

Dual mobility implant (Orthopedic Implant) Clinical Trial Eligibility Overview. Trial Name: NCT04092634 — Phase 4
Hip Dislocation Research Study Groups: Dual mobility, Single bearing, traditional hip implant
Hip Dislocation Clinical Trial 2023: Dual mobility implant Highlights & Side Effects. Trial Name: NCT04092634 — Phase 4
Dual mobility implant (Orthopedic Implant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04092634 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being enrolled in this research study?

"Correct. The clinicaltrials.gov website confirms that the medical research trial, which first appeared on November 1st 2017, is actively seeking participants right now. A total of 412 patients will be recruited from 4 different sites."

Answered by AI

Have Dual mobility implants attained regulatory authorization from the FDA?

"The safety of dual mobility implants is rated a 3 due to the fact it has already been approved in Phase 4 trials."

Answered by AI

Are there still openings available for participation in this investigation?

"Affirmative. The information published on clinicaltrials.gov indicates that this medical study is actively looking for participants, having been posted in November 1st 2017 and last updated October 27th 2022. 412 individuals must be enrolled at 4 different sites to complete the trial."

Answered by AI

How many facilities are presently housing this clinical investigation?

"Several medical institutions are participating in this trial, including Rush University Medical Center of Chicago, Illinois; New york University Medical Center in Manhattan; and Rothman Orthopaedic Institute of Philadelphia, Pennsylvania."

Answered by AI
~56 spots leftby Apr 2025